Nanoviricides Inc (NNVC) Stock Price, Quote & News

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gumm...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 937 6137

Website: www.nanoviricides.com

Address:

1 Controls Drive, Shelton, United States

STRAYNUT Nov. 15 at 9:43 AM

$NNVC NNVC Institutional Holdings Ownership Summary 8.18% https://www.nasdaq.com/market-activity/stocks/nnvc/institutional-holdings?page=1&rows_per_page=10

0 · Reply

STRAYNUT Nov. 14 at 11:12 PM

$NNVC 10-Q https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319584928&type=PDF&symbol=NNVC&cdn=8de2a8fe68b24916933b6fb88cf5f78d&companyName=NanoViricides+Inc.&formType=10-Q&formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&dateFiled=2025-11-14

0 · Reply

STRAYNUT Nov. 14 at 11:10 PM

$NNVC Form 8-K https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319585168&type=PDF&symbol=NNVC&cdn=b19bf074a5a8e0c35e2ccd3038e72f83&companyName=NanoViricides+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2025-11-14

0 · Reply

STRAYNUT Nov. 14 at 7:43 PM

$NNVC NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 https://finance.yahoo.com/news/nanoviricides-present-pharma-partnering-summit-133000676.html

0 · Reply

STRAYNUT Nov. 12 at 7:12 PM

$NNVC Form 424B5 https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319570043&type=PDF&symbol=NNVC&cdn=1a0b732d2a5f3588acd2f68f45c40c46&companyName=NanoViricides+Inc.&formType=424B5&formDescription=Prospectus+%5BRule+424%28b%29%285%29%5D&dateFiled=2025-11

0 · Reply

Love1010 Nov. 12 at 5:34 PM

$NNVC this stock is designed for wealth destruction!!!!!!!

0 · Reply

STRAYNUT Nov. 11 at 8:06 PM

$NNVC Short Interest (10/31/25) Shares Sold Short 117,190 Change from Last 153.27% Percent of Float 0.70% https://www.wsj.com/market-data/quotes/NNVC

0 · Reply

STRAYNUT Nov. 11 at 2:05 PM

$NNVC NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/nanoviricides-announces-pricing-of-6-million-registered-direct-offeri-1100053

1 · Reply

CalculatedSwing Nov. 10 at 8:54 PM

$CAPS sold $NNVC this morning, bought $CAPS .. reversal moves of a few dollars incoming!!!

0 · Reply

ZacksSCR Nov. 10 at 4:46 PM

$NNVC NanoViricides is preparing for a Phase 2 trial of NV-387 for Mpox, expected to begin in late 2025 or early 2026. Results could set the stage for stockpile programs and broader antiviral use. #NanoViricides #SmallCapStocks #Biotech https://youtu.be/7bJAJ82Dltc

2 · Reply

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

Nov 12, 2025, 5:01 PM EST - 2 days ago

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 11, 2025, 8:30 AM EST - 4 days ago

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 10, 2025, 8:30 AM EST - 5 days ago

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

Nov 5, 2025, 8:30 AM EST - 10 days ago

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

Nov 3, 2025, 8:30 AM EST - 12 days ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Oct 29, 2025, 8:45 AM EDT - 17 days ago

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

Oct 27, 2025, 8:45 AM EDT - 19 days ago

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

Oct 22, 2025, 8:45 AM EDT - 24 days ago

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

Oct 20, 2025, 8:45 AM EDT - 26 days ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

Oct 15, 2025, 8:45 AM EDT - 4 weeks ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

Sep 30, 2025, 8:45 AM EDT - 6 weeks ago

NanoViricides, Inc. Has Filed its Annual Report

Sep 11, 2025, 8:30 AM EDT - 2 months ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 9, 2025, 8:30 AM EDT - 2 months ago

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Aug 18, 2025, 8:30 AM EDT - 3 months ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Jul 30, 2025, 8:30 AM EDT - 3 months ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Jul 23, 2025, 8:30 AM EDT - 4 months ago

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Jul 21, 2025, 6:30 AM EDT - 4 months ago

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 16, 2025, 8:30 AM EDT - 4 months ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jun 18, 2025, 6:30 AM EDT - 5 months ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

Jun 4, 2025, 6:55 AM EDT - 5 months ago

NanoViricides Measles Drug Development Animal Study is Imminent

May 28, 2025, 6:30 AM EDT - 6 months ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 22, 2025, 6:30 AM EDT - 6 months ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 14, 2025, 6:30 AM EDT - 6 months ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 5, 2025, 6:30 AM EDT - 6 months ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Apr 29, 2025, 6:30 AM EDT - 7 months ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Apr 14, 2025, 6:30 AM EDT - 7 months ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

Mar 11, 2025, 6:30 AM EDT - 8 months ago

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Mar 4, 2025, 6:30 AM EST - 9 months ago

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

Feb 19, 2025, 6:30 AM EST - 9 months ago

NanoViricides, Inc. Has Filed its Quarterly Report

Feb 11, 2025, 6:30 AM EST - 9 months ago

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Jan 29, 2025, 6:30 AM EST - 10 months ago

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

Jan 27, 2025, 6:30 AM EST - 10 months ago

NanoViricides Engages CRO for Phase II Clinical Trial

Jan 13, 2025, 6:30 AM EST - 10 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Jan 8, 2025, 6:30 AM EST - 11 months ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Dec 23, 2024, 6:30 AM EST - 11 months ago

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

Nov 15, 2024, 6:30 AM EST - 1 year ago

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Nov 4, 2024, 12:00 AM EST - 1 year ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

Oct 22, 2024, 6:30 AM EDT - 1 year ago

NanoViricides President Dr. Diwan to Present at the PODD Conference

Oct 15, 2024, 6:30 AM EDT - 1 year ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

Oct 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Sep 30, 2024, 6:30 AM EDT - 1 year ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

Sep 26, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

Aug 26, 2024, 7:30 AM EDT - 1 year ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

Aug 19, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

Aug 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

Aug 1, 2024, 6:30 AM EDT - 1 year ago

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

Jul 24, 2024, 6:30 AM EDT - 1 year ago

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides

Jul 11, 2024, 6:30 AM EDT - 1 year ago

A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides

STRAYNUT Nov. 15 at 9:43 AM

$NNVC NNVC Institutional Holdings Ownership Summary 8.18% https://www.nasdaq.com/market-activity/stocks/nnvc/institutional-holdings?page=1&rows_per_page=10

0 · Reply

STRAYNUT Nov. 14 at 11:12 PM

0 · Reply

STRAYNUT Nov. 14 at 11:10 PM

0 · Reply

STRAYNUT Nov. 14 at 7:43 PM

0 · Reply

STRAYNUT Nov. 12 at 7:12 PM

0 · Reply

Love1010 Nov. 12 at 5:34 PM

$NNVC this stock is designed for wealth destruction!!!!!!!

0 · Reply

STRAYNUT Nov. 11 at 8:06 PM

$NNVC Short Interest (10/31/25) Shares Sold Short 117,190 Change from Last 153.27% Percent of Float 0.70% https://www.wsj.com/market-data/quotes/NNVC

0 · Reply

STRAYNUT Nov. 11 at 2:05 PM

1 · Reply

CalculatedSwing Nov. 10 at 8:54 PM

$CAPS sold $NNVC this morning, bought $CAPS .. reversal moves of a few dollars incoming!!!

0 · Reply

ZacksSCR Nov. 10 at 4:46 PM

2 · Reply

StockFlips Nov. 8 at 11:44 AM

$NNVC $YGMZ $RDHL 🔥🪽

0 · Reply

Love1010 Nov. 6 at 5:20 PM

$NNVC it looks so so bearish. How could you not short?

1 · Reply

ZacksSCR Nov. 6 at 3:26 PM

$NNVC: Getting Set for Phase 2 Trial of NV-387 in MPox… https://buff.ly/OgH9tJy

0 · Reply

GuttFilln Nov. 6 at 5:54 AM

$NNVC popped that Cherry!! Maybe a little upside and back down

0 · Reply

guardianofthegalaxy Nov. 5 at 6:11 PM

$SLS $NNVC Bulls here are loading the fucking boat and are not willing to miss the run on SLS when it launches. $NVCC means nothing to me.

0 · Reply

makedatbread88 Nov. 5 at 6:00 PM

$NNVC a lot of buying over the last month and heavy volume someone’s accumulating

0 · Reply

SPACEDAD Nov. 5 at 5:41 PM

$NNVC I'm up 44% on this. I'm probably going to just be greedy and wait for $3+. I'll sell at $1.95 if it manages to drop back there. My average is in the low 1.5s. It's not a massive position anyways.

1 · Reply

CalculatedSwing Nov. 5 at 4:48 PM

$SLS youre missing the run on $NNVC

0 · Reply

LeftyT Nov. 5 at 3:54 PM

$NNVC I've been significantly increasing my position on yesterday's dip and continue to average up today. The data continues to look impressive and a broad spectrum antiviral has huge unmet need and massive TAM. Long term funding support needs to be established, but at this price the reward potential far outweighs the risk.

0 · Reply

trekker314 Nov. 5 at 2:23 PM

$SLS Don't be blinded to potential competition. This story, however, reminds me of $NNVC which basically promised to kill many/most bad virus's in the world with their "wonder drug". Ha! It's an interesting read but with just a small study on mice they have many years to go. Still believe in GPS and 009. https://www.msn.com/en-us/health/other/cancer-drug-made-20-000-times-more-potent-in-breakthrough/ar-AA1PNqfY?ocid=entnewsntp&pc=U531&cvid=5305818641034c57b09c810e1a62b57b&ei=116

1 · Reply

Love1010 Nov. 4 at 8:42 PM

$NNVC goodbye $2'ssss

0 · Reply

d00bie Nov. 4 at 7:15 PM

$NNVC buy buy buy

0 · Reply

Market Cap	23.53M
Revenue (ttm)	0.00
Net Income (ttm)	-9.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	448,200
Avg Vol	275,318
Day's Range	N/A - N/A
Shares Out	17.43M
Stochastic %K	13%
Beta	1.15
Analysts	Strong Sell
Price Target	$7.00